IVD & LDT For Autoimmune Diseases Market - Global Forecast 2025-2032

The autoimmune disease testing market is experiencing significant change, as modern in vitro diagnostics and lab developed tests drive improved accuracy, workflow efficiency, and patient-focused outcomes. Senior decision-makers are now navigating a space defined by evolving policies, stricter validation requirements, and advanced analytics supporting strategic planning within autoimmune diagnostics.

Market Snapshot: IVD & LDT for Autoimmune Diseases Market

The IVD & LDT for Autoimmune Diseases Market expanded from USD 18.30 billion in 2024 to USD 19.26 billion in 2025, with projections indicating further growth at a CAGR of 5.25% to reach USD 27.56 billion by 2032. This trajectory underscores steady industry progress as diagnostics providers address the growing prevalence of autoimmune conditions, technological innovation, and dynamic regulatory environments guiding market stability and investment.

Scope & Segmentation

• Test Types: Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, Rheumatoid Factor. These tests underpin the diagnostic process, enabling clinicians to tailor approaches for disease identification and monitoring.
• Technologies: Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, Multiplex Immunoassay. Each technology enhances specificity and throughput, facilitating the detection and multiplexing of complex biomarkers.
• Product Types: In Vitro Diagnostic, Lab Developed Test. Offering standardized solutions alongside customizable LDTs allows labs flexibility to meet evolving clinical demands.
• End Users: Academic and Research Institutes, Diagnostic Laboratories, Hospital Laboratories, Reference Laboratories. These stakeholders drive assay adoption and influence test utilization, from research settings to routine clinical care.
• Applications: Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Type 1 Diabetes. Market breadth extends across leading autoimmune conditions, reflecting the demand for targeted and varied diagnostics.
• Sample Types: Dried Blood Spot, Plasma, Serum, Whole Blood. Choice of sample impacts test logistics and accessibility, with less invasive methods enabling remote sampling and wider reach.
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan). Regional diversity in infrastructure maturity and healthcare investment brings varied opportunities for diagnostics firms to develop region-specific strategies and partnerships.
• Company Profiles: Roche Diagnostics International AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Quidel Corporation, EUROIMMUN AG. These industry leaders shape technology development, regulatory alignment, and portfolio expansion within the segment.

Key Takeaways for Senior Decision-Makers

• Emerging automated and multiplex immunoassays optimize laboratory capacity, increase analytical sensitivity, and promote the simultaneous identification of multiple disease markers.
• Progress in regulatory harmonization streamlines multinational market entry, encouraging new product launches while maintaining essential validation protocols.
• Lab developed tests respond to nuanced clinical requirements by delivering customizable diagnostic solutions to complement commercial assay portfolios and address less common autoimmune presentations.
• Telehealth integration and remote specimen collection broaden access to diagnostic testing, increasing reach in remote or underserved regions and fueling growth among resource-limited populations.
• Differences in infrastructure investment mean developed regions focus on advancing companion diagnostics, while emerging markets prioritize scalable, affordable solutions to expand routine testing capacity.
• Strategic collaborations between diagnostics firms, academic groups, and pharmaceutical companies drive evolution in companion diagnostics and foster transition to value-based care models, further supporting clinical and operational outcomes.

Impact of Tariff Shifts on Market Strategies

Shifting US tariff policies effective from 2025 will recalibrate supply chain costs for autoimmune disease testing products. Import tariffs on assay reagents, kits, and analytical instrumentation may raise procurement and per-test expenses for laboratories. Key inputs such as purified antigens and advanced analyzers are particularly affected, prompting manufacturers and laboratories to reconsider sourcing models and explore local partnerships for greater control. Proactively refreshing supplier agreements, optimizing logistics, and engaging internal and external stakeholders are recommended measures to preserve margins and ensure consistent supply chains.

Research Methodology & Data Sources

This report uses a multi-stage analysis built on secondary research, industry regulatory and scientific reviews, and disclosures from leading diagnostics providers. In-depth interviews with laboratory directors, assay designers, and regulatory experts, supplemented by targeted surveys for practice-level insights, provide a comprehensive view of market trends. Data were triangulated and validated by industry specialists to ensure robust, actionable guidance.

Why This Report Matters

• Guides executive planning within evolving regulatory, technology, and procurement landscapes in autoimmune disease testing.
• Offers granular segmentation and regional differentiation, essential for identifying new growth segments and ensuring successful market positioning in IVD and LDT.
• Aligns practical recommendations with current innovation and operational trends, empowering senior leaders in diagnostics and biotechnology to inform near-term and long-term strategic choices.

Conclusion

The autoimmune disease diagnostics sector is progressing through technology integration and regulatory harmonization. Leaders equipped with these insights can bolster operational resilience, advance precise diagnostic capabilities, and maintain a competitive stance in a shifting market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.